Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

Brelovitug has previously received Orphan and PRIME designation from the European Medicines Agency.

A revolutionary advancement in cancer treatment at UH Seidman Cancer Center is dramatically reducing the time patients spend ...

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

In 2024, PF614-MPAR received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), and had its development bolstered by a $14 million multi-year award from the ...

Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...

What You Need to Know The global hydrogen water market is projected to grow from USD 2.5 billion in 2024 to USD 4.35 billion ...

Madison Keys attributed her breakthrough victory in securing her first Grand Slam title to extensive therapy, which she said ...